Dyne Therapeutics, Inc.
DYN
25 insider filings · Latest: May 13, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | May 14 8:05 PM | Johanna Friedl-NadererChief Commercial Officer | Sale | 228 | $18.36 | $4.2K | 154,353(D) | View → |
| May 13, 2026 | May 14 8:04 PM | Douglas KerrChief Medical Officer | Sale | 1,564 | $18.36 | $28.7K | 170,042(D) | View → |
| May 13, 2026 | May 14 8:03 PM | Erick LuceraChief Financial Officer | Sale | 1,448 | $18.36 | $26.6K | 123,925(D) | View → |
| May 13, 2026 | May 14 8:02 PM | John CoxDirector, CEO & President | Sale | 3,311 | $18.36 | $60.8K | 370,834(D) | View → |
| May 13, 2026 | May 13 8:57 PM | Cox John | Proposed Sale | 3,311 | $18.36 | $60.8K | — | View → |
| May 13, 2026 | May 13 8:55 PM | Lucera Erick | Proposed Sale | 1,448 | $18.36 | $26.6K | — | View → |
| May 6, 2026 | May 6 9:09 PM | Jason P RhodesDirector | Sale | 83,219 | $18.18 | $1.5M | 1,136,810(I) | View → |
| May 5, 2026 | May 6 9:09 PM | Jason P RhodesDirector | Sale | 11,600 | $18.03 | $209.1K | 1,154,054(I) | View → |
| May 4, 2026 | May 6 9:09 PM | Jason P RhodesDirector | Sale | 11,904 | $18.00 | $214.3K | 1,156,457(I) | View → |
| May 6, 2026 | May 6 8:43 PM | Atlas Venture Fund XI, LP | Proposed Sale | 43,621 | $17.47 | $762.1K | — | View → |
| May 6, 2026 | May 6 8:43 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 21,926 | $17.47 | $383.0K | — | View → |
| May 6, 2026 | May 6 8:42 PM | Atlas Venture Associates XI, LP | Proposed Sale | 428 | $17.47 | $7.5K | — | View → |
| May 6, 2026 | May 6 8:42 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 17,244 | $17.47 | $301.3K | — | View → |
| May 5, 2026 | May 5 8:39 PM | Atlas Venture Fund XI, LP | Proposed Sale | 6,081 | $17.71 | $107.7K | — | View → |
| May 5, 2026 | May 5 8:37 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 3,056 | $17.71 | $54.1K | — | View → |
| May 5, 2026 | May 5 8:36 PM | Atlas Venture Associates XI, LP | Proposed Sale | 60 | $17.71 | $1.1K | — | View → |
| May 5, 2026 | May 5 8:36 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 2,403 | $17.71 | $42.6K | — | View → |
| May 4, 2026 | May 4 9:00 PM | Atlas Venture Opportunity Fund I, LP | Proposed Sale | 2,466 | $17.39 | $42.9K | — | View → |
| May 4, 2026 | May 4 8:59 PM | Atlas Venture Fund XI, LP | Proposed Sale | 6,241 | $17.39 | $108.5K | — | View → |
| May 4, 2026 | May 4 8:59 PM | Atlas Venture Opportunity Fund II, LP | Proposed Sale | 3,136 | $17.39 | $54.5K | — | View → |
Page 1 of 6
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Feb 17 10:11 PM | John CoxDirector, CEO & President | Grant/Award | 285,000 | $16.00 | 285,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:10 PM | Douglas KerrChief Medical Officer | Grant/Award | 130,000 | $16.00 | 130,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:09 PM | Johanna Friedl-NadererChief Commercial Officer | Grant/Award | 90,000 | $16.00 | 90,000(D) | View → |
| Feb 12, 2026 | Feb 17 10:08 PM | Erick LuceraChief Financial Officer | Grant/Award | 105,000 | $16.00 | 105,000(D) | View → |